Jenna Ayyash
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jenna Ayyash has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Abbas Chaudhry
Crescent Theranostics, Anaheim, CA 982902, USA
1 shared publication - Ammar Chaudhry
AstraZeneca, Gaithersburg, MD 20878, USA
1 shared publication - Huma Muzaffar
Crescent Theranostics, Anaheim, CA 982902, USA
1 shared publication - Humam Shahare
College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas (H.S.).
1 shared publication - Maryam Gul
Crescent Theranostics, Anaheim, CA 982902, USA
1 shared publication - Mohannad Al-Hindi
College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72223, USA
1 shared publication
Latest Publications
- Open Access
From Oncogenesis to Theranostics: The Transformative Role of PSMA in Prostate Cancer
Prostate cancer, a leading cause of cancer-related mortality among men, is characterized by complex genetic and epigenetic alterations, dysregulation of oncogenic pathways, and a dynamic tumor microenvironment. Advances in molecular diagnostics and targeted therapies have significantly transformed the management of this disease. Prostate-specific membrane antigen (PSMA) has emerged as a critical biomarker, enhancing the precision of prostate cancer diagnosis and treatment. Theranostics, which integrates PSMA-targeted imaging with radioligand therapies, has shown remarkable efficacy in detecting and treating advanced prostate cancer. By leveraging the dual capabilities of PSMA-based diagnostics and therapeutic agents, theranostics offers a personalized approach that improves patient outcomes. This comprehensive review explores the latest developments in PSMA-targeted theranostics and their impact on the future of prostate cancer management, highlighting key clinical trials and emerging therapeutic strategies.
Open AccessFrom Oncogenesis to Theranostics: The Transformative Role of PSMA in Prostate Cancer
Prostate cancer, a leading cause of cancer-related mortality among men, is characterized by complex genetic and epigenetic alterations, dysregulation of oncogenic pathways, and a dynamic tumor microenvironment. Advances in molecular diagnostics and targeted therapies have significantly transformed the management of this disease. Prostate-specific membrane antigen (PSMA) has emerged as a critical biomarker, enhancing the precision of prostate cancer diagnosis and treatment. Theranostics, which integrates PSMA-targeted imaging with radioligand therapies, has shown remarkable efficacy in detecting and treating advanced prostate cancer. By leveraging the dual capabilities of PSMA-based diagnostics and therapeutic agents, theranostics offers a personalized approach that improves patient outcomes. This comprehensive review explores the latest developments in PSMA-targeted theranostics and their impact on the future of prostate cancer management, highlighting key clinical trials and emerging therapeutic strategies.